CD276 Monoclonal Antibody

The protein encoded by this gene belongs to the immunoglobulin superfamily, and thought to participate in the regulation of T-cell-mediated immune response. Studies show that while the transcript of this gene is ubiquitously expressed in normal tissues and solid tumors, the protein is preferentially expressed only in tumor tissues. Additionally, it was observed that the 3' UTR of this transcript contains a target site for miR29 microRNA, and there is an inverse correlation between the expression of this protein and miR29 levels, suggesting regulation of expression of this gene product by miR29. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Introducing the CD276 Monoclonal Antibody, a cutting-edge product designed to revolutionize the field of immunotherapy. This meticulously crafted antibody is specifically engineered to target CD276, a cell surface protein that plays a crucial role in immune regulation and tumor progression.

With its exceptional specificity and high affinity, the CD276 Monoclonal Antibody offers unparalleled precision in selectively binding to CD276-expressing cells. This enables the antibody to effectively modulate immune responses, thereby enhancing anti-tumor immunity and potentially inhibiting tumor growth.

The CD276 Monoclonal Antibody boasts a robust formulation, ensuring stability and reliability throughout its usage. Its exceptional purity and low endotoxin levels guarantee optimal performance and minimize any potential adverse effects.

This groundbreaking product has undergone rigorous testing and validation, demonstrating remarkable efficacy in preclinical studies. Its potential therapeutic applications span a wide range of malignancies, making it a versatile tool for researchers and clinicians alike.

Furthermore, the CD276 Monoclonal Antibody is manufactured in compliance with stringent quality control standards, ensuring consistent and reproducible results. Its user-friendly format allows for easy integration into various experimental protocols, facilitating seamless incorporation into ongoing research endeavors.

In summary, the CD276 Monoclonal Antibody represents a significant advancement in the field of immunotherapy. Its exceptional specificity, stability, and efficacy make it an indispensable tool for researchers and clinicians seeking to unravel the complexities of CD276-mediated immune regulation and explore novel therapeutic avenues. Embrace the future of immunotherapy with the CD276 Monoclonal Antibody and unlock new possibilities in the fight against cancer..